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Abstract
Complications of acute myocardial infarction are different and life threatening.
Prompt diagnosis and therapy are essential. In this, chapter we will analyse mechani‐
cal complications, such as ventricular free wall rupture, ventricular septal defect, pap‐
illary muscle rupture, ischaemic mitral regurgitation, left ventricle aneurysm, and
cardiogenic shock.
Keywords: Mechanical complications, ventricular free wall rupture, ventricular septal
defect, papillary muscle rupture, ischaemic mitral regurgitation, left ventricle aneur‐
ysm, cardiogenic shock, remodelling
1. Introduction
Complications of acute myocardial infarction are different and sometimes life threatening.
We can globally classify them in five categories: (1) ischaemic complications, which include
infarct extension, recurrent infarction, and post infarction angina; (2) arrhythmic complica‐
tions, in terms of atrial or ventricular arrhythmias, and sinus or atrioventricular node dys‐
function; (3) embolic complications towards central nervous system or peripheral
embolization; (4) inflammatory disturbances, such as pericarditis; (5) mechanical complica‐
tions, as myocardial rupture, mitral valve dysfunction, ventricular aneurysms and cardiogenic
shock up to heart failure.
Since the last years of the eighteenth century, many physicians discovered these clinical
entities, firstly during autopsy, and progressively by doing pioneristic surgical efforts, starting
by suturing heart wounds, and gradually trying to apply similar techniques on the infarcted
heart.
Mechanical complications of myocardial infarction are direct consequences of anatomopatho‐
logical changes occurring in ischaemic cardiac tissue. After a coronary occlusion, there is a lack
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in perfusion and in oxygen supply that cause functional, morphological, and biochemical
alterations. In the first 30 minutes from the occlusion, reversible changes happen; macroscop‐
ically and microscopically there are no grossly damages yet, but myofibrils start to relax, and
cells start to suffer. After half an hour, ischaemic necrosis begins, and the irreversible damage
occurs. Complete necrosis of myocardial cells requires at least 2–4 hours, or longer, depending
on the presence of collateral circulation, persistent or intermittent coronary arterial occlusion,
pre-conditioning, and individual demand for oxygen and nutrients. The principal mechanism
is coagulative necrosis, with neutrophil infiltration, oedema, and loss of myofibrils. After 6–
12 hours, loss of vitality is complete. In one week, macrophagic phagocytosis and collagen
disruption begin, and tissue becomes weaker; that is the most dangerous step in which heart
ruptures are more frequent [1, 2, 3].
The irreversible damage starts at a subendocardic level, and when the ischemia is widespread,
necrosis moves forward, involving the adjacent tissue both in width and in thickness. If
coronary flow is promptly restored while the damage is still reversible yet, the cells' vitality
could be preserved. On the other hand, reperfusion damage could be present by generating
free oxygen radicals and apoptosis activators.
After a couple of weeks, granulation tissue and neoangiogenesys begin, up to the formation
of a scar in about two months from myocardial infarction. Remodelling of myocardial tissue
is the final step; both infarcted and non-infarcted regions change in dimensions, thickness, and
shape, with hypertrophy and dilatation of the myocardial wall, and with the possible forma‐
tion of an aneurysm. Remodelling could be seen as a sort of haemodynamic compensation;
nevertheless, degenerative changes in myocardial tissue may cause a depression in regional
and global contractility, with a final lack in myocardial function [1, 2, 3].
As we will discuss, on a clinical level, signs and symptoms of mechanical complications of
myocardial infarction may vary according to the seriousness of the damage, going from rare
asymptomatic medical cases, through plainly symptomatic patients showing classical chest
pain, up to more frequent catastrophic, and even sudden onset with cardiogenic shock. Because
of these, a prompt diagnosis is important. While ECG may demonstrate the presence of an
infarction and help locate the ischaemic lesion, transthoracic echocardiography with Doppler
is the modality of choice for bedside diagnosis, capable of detecting heart ruptures, as well as
valve defects or ventricular motion abnormalities. Its immediate availability and the detailed
information it provides are fundamental in the management of these patients, helping in the
decision-making process. The use of other diagnostic tools, such as angiography, is subdued
to haemodynamic stability of the patient [3].
As far as therapy is concerned, most of all mechanical complications of myocardial infarction
require an urgent surgical approach. Meanwhile, initial management with medical therapy
should be administered immediately, in order to improve systemic and coronary perfusion,
and stabilise the haemodynamic status. Supplement oxygen and mechanical ventilatory
support while necessary should be provided, as well as analgesic therapy, in order to control
pain and reduce sympathetic tone; crystalloid infusion should be administered when hypo‐
tension and relative hypovolemia is present, together with inotropic agents. Many more
pharmacologic agents are useful, depending on every different clinical presentation, but the
positioning of an intra-aortic-balloon pump (IABP) is always a support of choice in order to
Coronary Artery Disease - Assessment, Surgery, Prevention216
reduce cardiac workload and increase supply of oxygen by increasing coronary perfusion
during diastole and reducing the after-load during systole [4].
Survival depends primarily upon the rapid recognition of each complication and upon an
immediate therapy. Even if operative mortality remains high, surgery is the essential tool to
avoid a fatal outcome.
In this chapter, we will analyse mechanical complications of myocardial infarction, such as
ventricular free wall rupture, ventricular septal defect, papillary muscle rupture, ischaemic
mitral regurgitation, left ventricle aneurysm, and cardiogenic shock. We will also deal with
therapies for heart failure, and make a brief digression upon strategies against myocardial
remodelling.
2. Left ventricular free wall rupture
The first description of left ventricular free wall rupture appeared in 1647 by William Harvey,
but until 1970, with operations managed by the teams of Hatcher and FitzGibbon, no successful
surgery was done [5, 6].
Left ventricular free wall rupture (LVFWR) is the most frequent presentation of myocardial
rupture: it occurs up to ten times more frequently than septal or papillary muscle rupture, and
mostly hits the lateral midventricular wall along the apex to base axis (the incidence of right
ventricular free wall rupture is very low, roughly 0.44%). Free wall rupture may occur at any
time after myocardial infarction, most frequently after 3–7 days, when coagulative necrosis,
neutrophil infiltration, and tissue lysis make myocardium weaker. Moreover, an increase in
wall tension may overcome the tensile strength of the weakened wall. However, at least 1/4 of
heart rupture occurs within the first 24 hours. Interstitial oedema, damage to collagen network
and myocyte apoptosis are proposed mechanisms [7].
The real incidence of this complication is unknown, although the reported incidence is
increasing (1–4%) among patients surviving hospital admissions due to an increment of the
availability of non-invasive diagnostic tools. Free wall rupture accounts for 6–17% of in-
hospital mortality [8]. The National Registry of Myocardial Infarction (NRMI) shows an
elevated incidence of in-hospital mortality among patients treated with thrombolytic therapy
(12.1%) than patients who were not treated (6.1%) [9]. In the Thrombolysis in Myocardial
Infarction Phase II (TIMI II) trial, 16% of patients died within 18 hours of therapy. Moreover,
patients who were treated with PTCA had an incidence of free wall rupture lower than that
of patients receiving thrombolytic therapy [10].
Risk factors are age (usually over 60 years old), gender (female), a history of hypertension, and
the absence of ventricular hypertrophy. Moreover, LVFWR occurs mostly after an ST elevation
myocardial infarction (STEMI), and in areas lacking of fibrosis (that means in patients without
history of previous angina or myocardial infarction). These last associations suggest that the
size of necrosis and the absence of collateral blood flow (with lack of previous ischaemic
symptoms) are important determinants in the aetiology of heart rupture [8].
To understand the clinical presentation of the LVFWR, it is worthy to speak about the
morphological pattern of rupture. Pathologically, Perdigao and associates described four types
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of ruptures: the type I, or direct rupture, is a single dissection of the wall in only one direction
and without dissection or blood infiltration (Fig. 1); type II is represented by a multiple
dissection, with a multicanalicular trajectory and an extensive haemorrhagic infiltration of
neighbouring tissue (Fig. 2); in type III, rupture is protected either by an intracardiac thrombus
or by adhesions on the epicardial side (Fig. 3); type IV is characterised by an incomplete
rupture, that doesn't cross the thickness of the ventricular wall, creating an intramural
haematoma [12]. However, Becker and van Mantgem proposed a different classification that
could be connected to the clinical presentation: acute, subacute, and chronic [13]. The acute
rupture (also called "blow-out" rupture, corresponding to Perdigao type I-II) is characterized
by a massive haemopericardium (Fig. 4); the presentation is dramatic, with sudden and
recurrent or persistent chest pain and a rapid deterioration into electro-mechanical dissociation
caused by pericardial tamponade. A severe jugular venous destention and cyanosis may be
present. Death occurs within a few minutes. When the rupture area is smaller, and temporarily
sealed by thrombus or pericardial adhesions, a subacute onset happens (also called “ooze”
rupture or Perdigao type III, and occurs in 30–40% of cases). Clinical presentation may involve
the gradual onset of signs and symptoms of cardiac tamponade. A variety of other signs may
be present, such as arrhythmias, a severe hypotension, syncope, and, eventually, cardiogenic
shock, but also malaise and nausea for few days.
A chronic rupture occurs when the leakage of blood is slow and when surrounding pressure
on the epicardium temporarily controls the haemorrhage, with the formation of a false
aneurysm (or pseudoaneurysm). This is a rare entity and usually occurs within three months
after myocardial infarction. Clinical presentation, in this case, is represented by congestive
heart failure, recurrent or persistent chest pain, ventricular arrhythmias, and even emboliza‐
tion [14].
Perdigao type IV (intramural haematoma) has no different presentation from the usual
infarction.
Perdigao Becker and van Mantgem
Type I
Acute (“blow-out”) rupture
Single dissection of the wall, in only one




Multiple dissection, with a
multicanalicular trajectory and an





Rupture is protected either by an
intracardiac thrombus or by adhesions
on the epicardial side
Fig. 3
Chronic rupture (pseudoaneurysm) Pressure on the epicardium temporarilycontrols the haemorrhage
Type IV Intramural haematoma
Table 1. Nema
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Figure 1. Perdigao type I, a single dissection of ventricular free wall
Figure 2. Perdigao type II, multicanalicular trajectory of rupture
Mechanical Complications of Myocardial Infarction
http://dx.doi.org/10.5772/61373
219
Figure 3. Perdigao type III, rupture is sealed by pericardial adhesions
Early diagnosis is improved by the use of transthoracic echocardiography, the fastest and most
useful diagnostic test, with a high diagnostic sensitivity (≥ 70%) and specificity (> 90%). The
most frequent finding is the presence of a pericardial effusion (> 5 mm), high-density intra‐
pericardial echoes, right atrial or right ventricular wall compression with tamponade, and, in
50% of cases, visible wall defects [15]. The role of the invasive diagnostic tools is still unclear
and depends on the haemodynamic stability of the patient. Most of the time, the definitive
diagnosis is made at surgery. Generally, when Perdigao type I, II, III, and IV are non-haemo‐
dynamically stable they require a surgical approach. Type IV in haemodynamically stable
patients can be treated conservatively [11, 17, 18, 19].
The first objective of treatment is to reach haemodynamic stability. Rapid infusions of
crystalloid along with inotropic agents may help to achieve this; pericardiocentesis may be
carried out prior to surgery and not only may confirm a haemorrhagic effusion, but also may
decrease the threat of tamponade. Placement of IABP should be done [20].
Surgical repair of the rupture site is the definitive treatment, and it can be administered in
different ways and with different techniques. Traditional and standard repair involves
performing infartectomy (including the area hit by the rupture) and reconstructing the
ventricle or close the damage with simple pledgeted suture (Fig. 5), with or without cardio‐
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pulmonary bypass. Both techniques have a shortcoming: in the first case, a ventricular cavity
distortion may damage the ventricular function; on the other hand, stitches are placed in a
necrotic—and so weaker—tissue. Different authors heave recently reported newer surgical
strategies, usually performed in the presence of oozing or sealed rupture (type III), by using
different biological materials such as pericardium (Fig. 6) and newer acellular xenogeneic
extracellular matrix patches, and non-biological patches made of polyethylene terephthalate
polyester fibre (Dacron) or polytetrafluoroethylene fluoropolymer resin (Teflon). Suturless
techniques with fibrin tissue-adhesive collagen fleece, and Gelatin-Resorcin Formaldehyde
glue are described [12, 16, 21, 22, 23].
In the matter of chronic rupture, the treatment of choice is still surgery, but obviously the
timing depends on the balance between risks and benefits. Pseudoaneurysm can be repaired
by the closure of the neck or by using a patch (similar to true aneurysm). Percutaneous
approaches (by using the AmplatzerTM occluder) are described as well [24].
The mortality rate is significantly high. It is strictly linked to the preoperative haemodynamic
condition of patient and to a prompt diagnosis.
Figure 4. Haemopericardium
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Figure 5. The damage has been closed with simple pledgeted suture
Figure 6. The damage has been sealed by using a pericardial patch
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3. Interventricular septal rupture
Ventricular septal defect (VSD), firstly described by Latham in 1845 [25], is a serious compli‐
cation of myocardial infarction that is little less frequent than free wall rupture. Its incidence
has been estimated between 1% and 2% of all myocardial infarctions even if the advent of
reperfusion therapy has decreased this value below 0.5%. However, the mortality is still high,
with 60–70% of patients dying within the first 2 weeks, and less than 10% survives after 3
months [26].
As for free wall rupture, risk factors for septal rupture include advanced age, hypertension,
and no previous myocardial infarction or angina.
The acute rupture occurs 3–7 days after a huge transmural infarction, with the weakening of
the septal wall, but the median decrease below 24 h with the use of thrombolysis. Late rupture
is possible (as long as 2 weeks). Pathophysiologically, this results in a left-to-right shunt with
diversion of blood flow towards pulmonary circulation. Systemic vasoconstriction in response
to peripheral hypotension and hypoperfusion worsens the shunt. As a consequence, low
cardiac output and cardiogenic shock occur [2].
Classification of the defect are of three types: type I ruptures show an abrupt tear in the wall
of normal thickness; in type II, the infarcted myocardium erodes before the rupture, and is
covered by thrombus; type III shows perforation of an aneurysm grown after infarct healing.
Moreover, defects can be classified in two other categories: simple and complex. Multiple
defects may be present in 5–11% of cases, and are probably caused by infarct extension. Simple
rupture is a discrete lesion, with holes located at a similar level in both ventricles and in a linear
path. This is the typical pattern of an anterior infarction and usually hits the part in which the
septum meets the free wall. On the other hand, inferior infarction usually leads to a complex
type, which presents a meandering dissection path between ventricles and extensive haemor‐
rhage in the nearby tissue that occurs near the base of the heart. Midseptal defects are rare and
are usually elicited from the occlusion of a perforating artery [4].
In both cases, rupture may vary in size from mm to cm. This determines the magnitude of left-
to-right shunting, influencing the clinical presentation (from asymptomatic to cardiogenic
shock), and the likelihood of survival. Signs and symptoms may include recurrent chest pain
and dyspnoea, but even a precipitous onset of haemodynamic compromise characterised by
hypotension and biventricular failure (often predominantly right-sided failure), up to cardio‐
genic shock is possible. At physical examination, a harsh and loud pansystolic murmur at the
left lower sternal border is present in over 90% of cases. A palpable thrill can be detected in
up to 50% of patients [27].
ECG shows changes associated to myocardial infarction and may help to correlate the
localization of infarction with the type of septal rupture.
Historically, the gold standard diagnostic tool was right cardiac catheterization using a Swan-
Ganz catheter, useful also to differentiate among other clinical entities (mitral ischaemic
regurgitation and papillary muscle rupture). In septal rupture, it is easy to find oxygen
saturation step-up between the right atrium and pulmonary artery greater than 9% (in
papillary rupture, giant V-waves in pulmonary artery wedge pressure are shown). Nowadays,
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the use of echocardiography (both transthoracic and transesophageal) has almost replaced this
diagnostic tool. Doppler may easily and accurately identify the location, the size, and the
presence of the shunt, indeed, with 100% specificity and 100% sensitivity. It may also assess
the ventricles function and estimate the right ventricle systolic pressure. The use of angiogra‐
phy is debatable; it can provide important information about coronary lesions, but, on the other
hand, may delay the surgical treatment [28].
Kirklin and colleagues reveal that nearly 25% of patients with post infarction septal rupture
and no surgical intervention died within the first 24 hours, 50% died within 1 week, 65% within
2 weeks, 80% within 4 weeks [28]; only 7% lived longer than one year. In the GUSTO-I trial,
the 30-day mortality rate was lower in patients treated with surgical repair than in patients
treated only medically (47% vs. 94%). The same results for the 1-year mortality rate (53% vs.
97%) [29]. In the SHOCK trial, the in-hospital mortality rate was higher in patients with
cardiogenic shock due to septal rupture (87.3%) than in patients with cardiogenic shock from
all other causes (59.2% with pure left ventricle failure and 55.1% with acute mitral regurgita‐
tion) [30].
The optimal approach varies with the clinical presentation. Medical therapy is considered to
be a support tool in the offing of surgery, and is usually managed with the use of pharmacologic
support with vasodilators (which reduce afterload, thereby decreasing left ventricular
pressure and the left to right shunt), inotropic agents (which may increase the cardiac output),
diuretics, and IABP. In patients with cardiogenic shock, death is inevitable in the absence of
urgent surgical intervention. Delayed elective surgical repair is feasible in patients with heart
failure without shock, but an unpredictable and rapid deterioration is always lurking in
general; adverse outcomes are correlated with advanced age and a lengthy delay between
septal rupture and operation [28].
The surgical approach has been performed since 1959 when Cooley and associates performed
the first successful surgical repair through a right ventriculotomy with incision of right
ventricular outflow tract [31]. Disadvantages of this approach were suboptimal exposure and
failure to eliminate the bulging segment of infarcted left ventricular wall. Later, Heimbecker
[32] and colleagues developed a different technique, performing a left ventriculotomy.
Nowadays, multiple techniques are described. Apical amputation is simpler, but apical defects
are rare. This technique was proposed in the 1970s by Daggett [33]. After the resection, the
ventricular free walls are linked using Teflon strips. Other techniques involve infarct exclusion
and defect closure with a patch (biological or synthetic) using both stitches and glues [34].
Preservation of the geometric configuration of the ventricles is an important target, together
with the closure of the defect.
Even a percutaneous approach has been considered, mostly in order to close contingent
residual defects (residual defects are present in about 28% of survived patients) or sometimes
used for the acute stabilization of critically ill patients. However, no long-term outcome data
about this mini-invasive technique are available [35].
Despite continuous advances in surgical approaches, operative mortality remains high (20–
50%), with no clear differences between different techniques (Fig. 7–13) [34].
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Figure 7. Anterior repair of VSD [Adapted from Chikwe J, Beddow E, Glenville B. Cardiothoracic Surgery. Oxford
University Press 2006]
Figure 8. VSD, anterior surgical approach
Mechanical Complications of Myocardial Infarction
http://dx.doi.org/10.5772/61373
225
Figure 9. VSD closure with synthetic patch
Figure 10. VSD closure with synthetic patch
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Figure 11. Ventricular free walls are linked using Teflon strips
Figure 12. Apical resection [Adapted from Chikwe J, Beddow E, Glenville B. Cardiothoracic Surgery. Oxford Universi‐
ty Press 2006]
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Figure 13. Posterior repair of VSD [Adapted from Chikwe J, Beddow E, Glenville B. Cardiothoracic Surgery. Oxford
University Press 2006]
4. Papillary muscle rupture
Papillary muscle rupture (PMR) is a rare entity and occurs in about 1% of patients with acute
myocardial infarction. It accounts for 5% of infarct-related deaths. Mortality may be as high
as 50% in the first 24 h, and up to 80% in the first week, when only medical treatment is applied.
Timing of rupture stays in a range between 1 and 14 days, but 80% occurs in 7 days [36].
Rupture of papillary muscles results from infarction of the muscle itself and leads to an
ischaemic mitral regurgitation by lack of leaflet tethering (Carpentier type II, see next chapter
for further information).
PMR is most common with an inferior myocardial infarction, and the posteromedial papillary
muscle is most often involved (6 to 12 times more frequently than anterolateral papillary
muscle); that's because of its single blood supply through the posterior descending coronary
artery (anterolateral papillary has a dual blood supply, instead, from the left anterior descend‐
ing and left circumflex arteries) [36, 37, 39].
Among risk factors, there is, once again, the absence of a previous infarction in medical history.
PMR may be complete, with a massive mitral regurgitation and rapid onset of symptoms up
to hemodynamic collapse and death, or partial, with a moderate to severe mitral regurgitation.
Clinical presentation may vary according to the completeness of rupture, but usually presents
dyspnoea, hypotension, acute pulmonary oedema, and cardiogenic shock. At the physical
examination, a soft murmur without thrill may be present, even if the absence of new heart
murmur does not exclude the diagnosis.
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The gold standard in diagnosis is Doppler transthoracic and transesophageal echocardiogra‐
phy, with the evidence of a tear in papillary tissue and the flail of mitral leaflet leading to severe
mitral regurgitation (Fig. 14, 15). Left ventricular function is usually hyperdynamic as a result
of ventricular contraction against the low impedance left atrium. Haemodynamic monitoring
with a Swan-Ganz catheter can reveal large (> 50 mmHg), early V waves in the pulmonary
capillary wedge pressure, and no increase in oxygen saturation from right atrium to right
ventriculum (useful to conduct differential diagnosis with septal rupture) [36, 37, 38].
Figure 14. Echo findings in complete papillary muscle rupture
Figure 15. Echo findings in complete papillary muscle rupture
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The only real treatment for papillary muscle rupture is surgery, although it is high risk
(operative mortality up to 20–25%) [37]. Medical therapy could be performed in order to reach
a hemodynamic stability prior to emergency surgery, and includes aggressive afterload
reduction in order to decrease the regurgitant fraction by using nitrates, sodium nitroprusside,
diuretics, and IABP.
The surgical technique depends upon the location and the completeness of the rupture. With
partial PMR, some surgeons prefer to stabilise the patient and delay surgery for 6–8 weeks
after myocardial infarction to avoid operating on the necrotic myocardial tissue. However, an
acute intervention in patients that cannot be stabilized must be considered. A surgical repair
of the papillary muscle head is really rare, but possible, with pledgeted sutures and the
addition of glue to strengthen the repair. Mitral valve repair rather than replacement should
be attempted when there is no papillary muscle necrosis [36, 37].
Figure 16. The excised mitral valve showing complete rupture of the papillary muscle
5. Ischaemic mitral regurgitation
Ischaemic mitral regurgitation (IMR) is a functional entity that occurs in 8% to 50% of patients
after myocardial infarction. Unlike the structural mitral regurgitation, here the valve leaflets
and valvular apparatus are normal, even if the coexistence of coronary artery disease and non-
ischaemic mitral disease has led to a poor understanding of this clinical entity [40].
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Carpentier described three general types of mitral regurgitation according to different
pathophysiologic mechanisms: type I, in which there is a normal leaflet motion, and regurgi‐
tation is caused by annular dilatation from ischemia of adjacent ventricular wall or by leaflet
perforation; type II, in which we can find an increased leaflet motion, with a prolapse of valve
leaflet (in this case, regurgitation is caused either by papillary muscle rupture or in papillary
muscle elongation due to chronic ischemia, and usually lead to an asymmetric leak); type IIIa,
with leaflet restriction during systole and diastole (not seen in ischaemic mitral regurgitation);
type IIIb, leaflet restriction only during systole caused by a dysfunction of ventricular wall,
dilated after ischaemic injury, with systolic tethering of papillary muscle (as a consequence,
there's a failure in mitral coaptation).
IMR could be acute or chronic, but both result from ischemia of ventricular wall and missed
coaptation. The remodelling secondary to acute and chronic ischemia remains the principal
mechanism for IMR and depends on apical tethering and an excessive tenting volume, which
cause coaptation failure of the mitral leaflets. Mild-to-moderate mitral regurgitation is often
clinically silent and detected on Doppler echocardiography performed during the early phase
of myocardial infarction.
Risk factors are advanced age, female sex, large infarct, multivessel coronary artery disease,
and, unlike other mechanical complications, history of a previous myocardial infarction or
recurrent ischemia.
The acute onset of severe IMR is a life-threatening complication and arises from a few hours
to weeks after myocardial infarction; in this case, a sudden volume overload is imposed on the
left ventricle, increasing preload and a small increase in total stroke volume. Acute mitral
regurgitation usually results from the rupture of papillary muscles or chordae tendineae:
haemodynamic deterioration is sudden, because no compensatory structural changes in
atrium and ventricle are possible. Pulmonary congestion, as well as cardiogenic shock, may
occur. Clinical features include pulmonary oedema, chest pain, and dyspnoea. A new pan‐
systolic murmur can be detected, best heard at the apex [40, 44].
Chronic IMR occurs as a consequence of ventricular dilatation secondary to ischaemic
ventricular remodelling (both regional or global), with papillary muscle displacement and
failure of leaflet coaptation. During chronic onset of the disease, the left atrium and ventricle
may develop an offsetting hypertrophy and dilatation. Enlargement of the left atrium allows
volume overload, but may cause arrhythmias, such as atrial fibrillation, and the formation of
thrombi. Until systolic dysfunction prevents effective ventricular contraction, patients are
asymptomatic. After that, exertional dyspnoea and fluid retention may be present [40].
The gold standard diagnostic tool is echocardiography, both transthoracic and transeosopha‐
geal, which assess mitral valve apparatus, the mechanism of regurgitation, and the ventricular
function [3, 15]
Medical therapy may have a supportive role in case of acute onset of mitral regurgitation, while
in chronic cases it is useful in decreasing the regurgitant volume and improve ventricular
function by using ACE-inhibitors, and to reduce remodelling by using beta-blockers. Most
patients with acute mitral regurgitation are managed with percutaneous coronary intervention
Mechanical Complications of Myocardial Infarction
http://dx.doi.org/10.5772/61373
231
(PCI) or thrombolysis. Surgery is usually reserved for acute and severe cases, which do not
ameliorate after these approaches, and for chronic patients symptomatic for coronary disease.
Repair versus replacement of the mitral valve is still debatable. Mitral valve repair is generally
preferred whenever possible based on valve pathology and patient stability: it avoids long-
term anticoagulation, decreases infective endocarditis risk, and provides greater leaflet
durability. Among repairs, different techniques are available, but annuloplasty with prosthetic
ring is the gold standard [41, 42]. On the other hand, valve replacement is usually reserved for
situations where the valve cannot be reasonably repaired, or when repair is unlikely to be
tolerated clinically. Moreover, it being a faster procedure is better in high-risk surgical
candidates. Mitral valve replacement could be managed by using the chordal-sparing techni‐
ques, a range of procedures that permit the resuspension of chordae and the preservation of
subvalvular anatomy [43].
Percutaneous approaches are available, but often limited to patients with lots of comorbidity
and a poor surgical outcome [40].
6. Left ventricular true aneurysm
The earliest reports of a ventricular aneurysm appeared in 1757, during an autopsy managed
by Galeati and Hunter; but the first surgical approach to this pathology was performed in 1942
by Beck.
A true aneurysm is the result of the gradual thinning and the expansion of the scarred left
ventricular wall after transmural infarction. This is a different entity from a pseudoaneurysm,
which does not contain all the three layers of the myocardium and is frequently lined by
pericardium and mural thrombus [45, 47, 49].
The 85% of true aneurysm is located anterolaterally, near the apex of the heart. Two types of
true aneurysm are present: a traditional aneurysm, namely a region of myocardium with an
abnormal diastolic contour and a systolic dyskinesia, with a paradoxic bulging; and a func‐
tional aneurysm, in which bulging is not present, but is characterised by large areas of akinesia,
that affects ventricular function. They originate from two distinct phases of myocardial
infarction. First, an early expansion phase defined as the deformation or stretch of infarcted
myocardium during the first week after the ischaemic injury: wall thinning due to the
degradation of collagen matrix and dilatation lead to an augmentation in both systolic and
diastolic wall stress, following LaPlace law, and to a greater request of oxygen supply. Fibre
stretching is progressive until fibrosis and scarring. Increased diastolic stretch, elevated
catecholamines and stimulation of natriuretic peptides may demonstrate increased fibre
shortening and myocardial hypertrophy as adaptive changes. The second phase is constituted
by late remodelling. Here, the aneurysm is composed of scar tissue; systolic and diastolic
ventricular dysfunctions are present, in fact aneurysm does not contract nor distend (this
impairs diastolic filling and increases left ventricular end-diastolic pressure). Mechanism of
compensation such as chamber dilatation, hypertrophy, and changes in ventricular geometry
lead to a poor contractile function, and eventually heart failure [46, 48]
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The incidence of true aneurysm is 10–35% after transmural myocardial infarction, even if it
may result from trauma, Chagas' disease, sarcoidosis, or may be congenital as well. Risk factors
seem to be the presence of a previous infarction in medical history and a decreased ejection
fraction (less than 50%).
Clinical presentation often involves angina (in more than 60% of patients, three-vessels
coronary disease is present), dyspnoea, and symptoms of congestive heart failure. Atrial and
ventricular arrhythmias may occur in the scar tissue, producing palpitations, syncope, and
even sudden death. A mural thrombus is often found (50%) [43, 44, 45, 50, 51, 52, 53].
Even if echocardiography is a useful diagnostic tool capable of identifying false aneurysm and
assessing ventricular function, angiography and left ventriculography is the gold standard,
estimating the size of aneurysm and evaluating cardiac function and kinesis, as well as
coronary status. Tomographic three-dimensional echocardiography and magnetic resonance
imaging are the most reliable means of evaluating left ventricular volume. Positron emission
tomography (PET) can be helpful in an early phase to differentiate true aneurysm from
hibernating myocardium with reversible dysfunction. Even magnetic resonance imaging can
be useful, but cannot assess coronary anatomy.
Medical therapy aims to minimise the remodelling of the left ventricle: both in acute and
chronic heart failure; ACE inhibitors may reduce ventricular wall stress, as well as ventricular
dilatation. Beta-blockers do the same. Nitrates may reduce hypertrophy, but it seems they don't
affect mortality.
Anticoagulation with warfarin is  indicated for patients  with a mural  thrombus.  Patients
should be treated initially with intravenous heparin, with a target aPTT of 50–70 seconds.
Warfarin is started simultaneously, and the INR target is 2–3 for a period of 3 to 6 months.
The use of anticoagulation without the presence of a thrombus is controversed. Anticoagu‐
lation should be reinitiated if a new thrombus develops, and an echocardiographic follow
up must be done [54].
Asymptomatic patients with a small aneurysm may be treated medically. However, an
aneurysm that occupies more than 25% of the ventricular surface may significantly affect the
global function. When refractory heart failure or ventricular arrhythmias are present, as well
in the presence of a huge aneurysm, surgery is indicated.
Resection of the aneurysm may be followed by conventional closure or newer techniques to
maintain LV geometry. In the plication technique, a direct closure of the aneurysm without
excision is performed; this is usually done for very small aneurysms without internal thrombus
[55]. Another conventional strategy, the linear repair, was first introduced by Cooley in 1958.
In this technique, the incision is extended round the aneurysm leaving a rim of scar tissue and
buttressed mattress sutures are placed successively. With this technique, changing ventricular
geometry is possible [55].
Other newer techniques aim to maintain ventricular geometry by using the external patch
(procedure performed by Daggett) or inverted T closure of ventriculotomy (as done by
Komeda) [56], or circular patch technique for posterior aneurysms [57]. Finally, endoaneur‐
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ysmorraphy, a procedure proposed by Jatene, Dor, and Cooley, positions an endocardial patch
in order to preserve both normal ventriculum and septal geometry [58, 59, 60].
Figure 17. Traditional aneurismectomy: Linear closure [Adapted from Chikwe J, Beddow E, Glenville B. Cardiothora‐
cic Surgery. Oxford University Press 2006]
Figure 18. Traditional aneurismectomy: Patch closure [Adapted from Chikwe J, Beddow E, Glenville B. Cardiothoracic
Surgery. Oxford University Press 2006]
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7. Cardiogenic shock and heart failure
Cardiogenic shock is a clinical syndrome characterised by end-organ hypoperfusion, due to a
rapid worsening of ventricular function.
It occurs in 5–8% of hospitalised patients with STEMI, and 12% of these cases are caused by a
mechanical complication of myocardial infarction. Cardiogenic shock may also occur in 2.5%
of non-coronary cases: any cause of acute, severe left or right ventricular dysfunction such as
acute myopericarditis, tako-tsubo cardiomyopathy, hypertrophic cardiomyopathy, acute
valvular regurgitation caused by endocarditis or chordal rupture due to trauma or degenera‐
tive disease, as well as aortic dissection, severe aortic or mitral insufficiency. Moreover, cardiac
tamponade or massive pulmonary embolism may lead to this kind of shock [60, 61, 62, 63, 64].
Risk factors are directly related to the principal trigger. In the context of myocardial infarction,
risk factors may include older age, hypertension, diabetes mellitus, multivessel coronary artery
disease, prior myocardial infarction or angina, anterior location of infarction, prior diagnosis
of heart failure, STEMI, and left bundle-branch block.
Considering the ischaemic aetiology of cardiogenic shock, pathological mechanism starts with
the ischaemic injury of myocite, with loss of effective contractility, and a systolic and diastolic
dysfunction. A decrease in cardiac output leads to a decrease in systemic and coronary
perfusion. A vicious cycle originates, with the worsening of hypoperfusion and the increasing
of infarcted regions of myocardium. To compensate the decrease in stroke volume and cardiac
output, sympathetic tone is increased, eliciting tachycardia, systemic vasoconstriction, and
increased contractility of the healthy non-ischaemic myocardium. This results in an increase
in the cardiac workload and oxygen consumption. When these compensatory mechanisms
cannot meet the increased demand, there's once again a progression in myocardial injury. Even
systemic inflammation may contribute to myocardial dysfunction, decreasing systemic
perfusion. The spiral worsening of ventricular function and a subsequent shock was thought
to occur after the loss of at least 40% of the left ventricular mass [60].
The definition of cardiogenic shock includes haemodynamic parameters, such as persistent
hypotension (systolic blood pressure < 90 mmHg, with severe reduction in cardiac index < 1.8
L/min/m2), elevated filling pressure, and pulmonary capillary wedge pressure < 15 mmHg.
Signs and symptoms include cool and sweaty extremities, cyanosis, decreased urine output,
and/or alteration in mental status. Haemodynamic abnormalities go from mild hypoperfusion
to profound shock, and the short-term outcome is directly related to the severity of the
haemodynamic derangement [60, 61, 62, 63, 64].
The diagnosis is usually made with invasive haemodynamic monitoring using pulmonary
artery catheterisation (Swan-Ganz catheter); however, Doppler echocardiography may help
to confirm the elevation of the left ventricle filling pressures, and may assess mechanical causes
of shock above all. ECG confirms ischaemic aetiology.
Therapies should not be delayed. On the pharmacological side, no drugs have been shown to
improve survival, but they are fundamental in supporting and stabilising the patients prior to
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the definitive therapy. Support includes inotropic and vasopressor agents, which should be
used in the lowest possible doses (higher vasopressor doses are associated with poorer survival
due to a combination between hemodynamic derangement and direct toxic effects).
IABP has long been a mainstay of mechanical therapy for cardiogenic shock [66, 67, 68, 69]. It
improves coronary and peripheral perfusion via diastolic balloon inflation and augments left
ventricular performance via systolic balloon deflation with an acute decrease in afterload.
Nowadays, the reported efficacy of this mechanical support in studies has been variable; some
studies, such as the IABP-SHOCK II trial have downgraded IABP, showing no significant
differences in treatment groups [71]. Despite this fact, IABP remains in wide use, driven by
substantial anecdotal evidence as well as meta-analytic results [70].
In the vicious cycle that characterises cardiogenic shock, revascularisation fulfills an important
role, increasing the likelihood of survival with good quality of life (in the randomized SHOCK
trial, a 13% increase in 1-year survival in patients assigned to early revascularisation was
found) [30]. Mechanical reperfusion may be obtained with a percutaneous approach (angio‐
plasty with or without stenting) or with surgical approach (coronary artery bypass grafting).
The optimal revascularisation strategy for patients with multivessel coronary artery disease
and cardiogenic shock is not clear. At large, immediate coronary artery bypass surgery is the
preferred method of revascularisation when severe triple-vessel or left main disease is present,
and should be performed when mechanical complications coexist. Percutaneous coronary
intervention of the infarct-related artery is recommended in the case of single or double-vessel
disease, or when surgery is not possible [60, 65]. In the STICH (Surgical Treatment for
Ischaemic Heart Failure) trial, the addition of coronary artery bypass surgery to medical
therapy reduced the most common modes of death (sudden death and fatal pump failure
events), with beneficial effects principally seen after two years [72].
Temporary mechanical circulatory support may theoretically interrupt the vicious spiral of
ischaemic damage, and allow for recovery of stunned and hibernating myocardium. This kind
of support involves circulation of blood through a device that drains venous blood and returns
it to the systemic arteries with pulsatile or continuous flow after passing a membrane oxy‐
genator. The major limitations of temporary mechanical circulatory support are device-related
complications and irreversible organ failure.
It is possible to distinguish between two main classes of devices with short-term and long-
term support. Short-term devices are usually placed in patients with acute heart failure, with
a refractory cardiogenic shock and/or mechanical complications of myocardial infarction.
Veno-arterial extra-corporeal membrane oxygenation (VA-ECMO) assists both ventricles and
provides a continuous flow with maintenance of a pulsatile arterial pressure unless the
circulation is completely supported by the cardio pulmonary bypass device. This pump may
be beneficial in cases of severe cardiogenic shock refractory to other pharmacological and
mechanical support measures, although its use has not been tested in randomised clinical trials.
In a recent meta-analysis, it is shown that VA-ECMO provides acceptable short-term survival
for adult patients with cardiogenic shock and stable long-term survival outcomes at up to 3
years. These benefits, however, must be considered alongside the significant associated risks
in the decision to institute this type of haemodynamic support [73, 74].
Coronary Artery Disease - Assessment, Surgery, Prevention236
Other short term supports are axial flow pumps, with pumps positioned across the aortic valve
to provide active support by transvalvular left ventricle assistance, placed with percutaneous
or peripheral surgical approach (e. g., The Impella Recover® - Impella CardioSystems GmbH,
Aachen, Germany), and the left atrial-to-femoral arterial left ventricular assist devices, with
percutaneously inserted transseptal and arterial cannulae connected to a centrifugal pump (e.
g., The Tandem HeartTM pVAD - Cardiac Assist Technologies, Inc., Pittsburgh, PA, USA) [75].
Studies have shown that these mechanical supports may reverse haemodynamic and meta‐
bolic parameters in cardiogenic shock more effectively than with standard IABP treatment
alone.
However, when end-stage heart failure occurs, cardiac transplantation remains the gold
standard, even if the lack of suitable donor organs significantly limits this therapeutic option.
Implantation of a long-term ventricular assist device as a bridge to transplantation or as a
destination therapy is an established life-sustaining treatment option for select patients [76,
77, 78, 79].
8. New therapeutic strategies against myocardial remodelling
As seen in the beginning of this chapter, at the bottom of any mechanical complication after a
myocardial infarction is the process that starts with an ischaemic injury and finishes with the
remodelling of the myocardial tissue. As a result of myocite apoptosis, fibrous tissue deposi‐
tion and the formation of a myocardial scar, heart failure occurs [2].
Although modest cardiomyocyte turnover occurs in the adult heart, it is insufficient for the
restoration of a normal contractile function after substantial cardiomyocyte loss, and even if
this cardiac remodelling can be slowed or sometimes reversed by intense pharmacological
therapy (thrombolysis, ACEi, beta-blockers, and statins), this process is often progressive.
Several studies aim to find new therapeutic strategies for daily practise against myocardial
remodelling. Many of them focused on biochemical patterns occurring during the remodelling
process, principally on the ischaemic-reperfusion injury, by searching strategies against the
generation of reactive oxygen species (ROS) in the ischaemic myocardium, or by interacting
with complex cytokines pathways [80].
On the other hand, stem cells therapy seems to be another new approach to the problem of
remodelling. Replacement and regeneration of functional cardiac muscle after an ischaemic
insult co
uld be achieved by either stimulating proliferation of endogenous mature cardiomyocytes
(reinitiating mitosis) or resident cardiac stem cells or by implanting exogenous donor-derived
or allogeneic cardiomyocytes. New strategies may consist of transplanted bone marrow-
derived cardiomyocyte or endothelial precursors, foetal cardiomyocytes, and skeletal myo‐
blasts [81, 82, 83, 84].
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